Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM – Research Report), Regulus (RGLS – Research Report) and Heron Therapeutics (HRTX – Research Report) with bullish sentiments.

Insmed (INSM)

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed, with a price target of $55.00. The company’s shares closed last Monday at $22.30, close to its 52-week low of $21.09.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 7.7% and a 41.7% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals.

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $50.00.

See Insiders’ Hot Stocks on TipRanks >>

Regulus (RGLS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Regulus today and set a price target of $2.00. The company’s shares closed last Monday at $0.20, close to its 52-week low of $0.19.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -33.3% and a 14.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Aquestive Therapeutics, and Oncternal Therapeutics.

Currently, the analyst consensus on Regulus is a Moderate Buy with an average price target of $1.21.

Heron Therapeutics (HRTX)

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Heron Therapeutics yesterday and set a price target of $60.00. The company’s shares closed last Monday at $8.53, close to its 52-week low of $7.85.

According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 8.9% and a 48.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, BioMarin Pharmaceutical, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Heron Therapeutics with a $35.67 average price target, implying a 337.7% upside from current levels. In a report issued on January 18, Jefferies also assigned a Buy rating to the stock with a $23.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on INSM:

• Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Colgate-Palmolive (CL) and Kohl’s (KSS)
• Analysts’ Top Financial Picks: Hope Bancorp (HOPE), Huntington Bancshares (HBAN)
• Analysts’ Opinions Are Mixed on These Technology Stocks: Apple (AAPL) and Seagate Tech (STX)
• What Do Grocery Outlet’s Newly Added Risk Factors Tell Investors?
• Tesla Earnings Preview: Monthly User Statistics Point to a Solid Q4